As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts. Daiichi ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

On Tuesday, Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) shares maintained a positive outlook as TD Cowen sustained its Buy rating and JPY46.00 price target on the company's stock.

Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with ...

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2 ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck and Eisai's Keytruda-Lenvima combo delivered a win in liver cancer.